Effects of new antipsychotics. In a study of 323 hospitalized adult psychiatric patients, the EEG-Ver Changes in patients with 19.1% and 13.3% of patients were not treated with Hesperidin antipsychotic drugs occurred. The risk of EEG abnormality among different antipsychotics varied widely and was particularly high with clozapine and olanzapine. The gr-Run event was clozapine, olanzapine, risperidone, followed by the first generation of antipsychotic and quetiapine. The authors found that significant risk factors for the classification of reqs Fill factors for high blood pressure, the use of a second-generation antipsychotics and a diagnosis of bipolar St Tion and Older people were. Station re patients, the risk of reqs Cases reduced co-treated with a benzodiazepine.
There was no correlation between dose and clinical response and an h Higher risk of EEG Ver Changes. EEG monitoring prior to the start of treatment with clozapine, after the optimal dose is reached, every 6 months, and in case of acute behavior Change recommended above antipsychotic treatment. 4th Conclusion Celecoxib Celebrex The p Pediatric population appears to be an hour Higher risk than adults for antipsychotic induced side effects. The safety profile of antipsychotics is crucial to the treatment strategy for children and adolescents with schizophrenia or bipolar St Tion, because of the long-term drug Sen therapy. Second-generation antipsychotics and the third are more than s Rs that the first generation agents, but they are often associated with side effects like weight gain and metabolic complications, increases hte prolactin levels associated EPS, sedation and cardiac effects sorgf Observed valid.
Where m Possible, it is important to use antipsychotics for p Diatrische patients are admitted, an L Ngere duration of treatment S r hrleisten weight. Table 4 shows the common antipsychotics and indicated for use in children and / or adolescents. Only risperidone and aripiprazole in the first line, the FDA’s treatments for children and adolescents with schizophrenia and bipolar patients with St Tion approved. However, risperidone caused significant weight gain in young, female During aripiprazole is thought to be more weight neutral. Olanzapine is an effective therapeutic agent with a good safety profile, but it will be validly monitored with a significant weight gain and metabolic complications that w Sorgf during the treatment Should be associated.
Further data are n IST to support the efficacy of quetiapine and ziprasidone, but at standard doses, these agents better reps Opportunity as risperidone and olanzapine in terms of weight gain, glucose metabolism, increases hte prolactin mirror, and EPS. The experience with aripiprazole is still limited, as is the recently introduced antipsychotic, but the efficacy data set and reps Close possibility that there may be a treatment of choice for p Pediatric patients with schizophrenia or bipolar St be Tion. Only a few randomized and controlled Lee examined the safety of antipsychotics in children and adolescents, despite the importance of the above data about the side effects with this therapeutic agent. However, analysis of safety data for the development of specific perm SSIGE.